Background: The evidence-based approach to medical care involves the explicit use of evidence on the magnitude of the effects of interventions to inform diagnostic and treatment decisions. This article critiques current mainstream guidelines on the management of hypertension in the elderly (aged 60 years and over) and presents an alternative evidence-based approach. Methods: Three major national and international guidelines for the management of hypertension from the United Kingdom (UK), the United States (US) and from a joint World Health Organisation/International Society of Hypertension (WHO/ISH) Working Party were appraised and the evidence on which they were based was reviewed. The relevant evidence was also assessed to determine the likely magnitude of risks and benefits of anti-hypertensive treatment in older people and an alternative approach to making treatment decisions, based on the New Zealand guidelines for the management of hypertension, is described. Results: Hypertension management guidelines from the UK, US and WHO/ISH made similar recommendations about which elderly patients should be treated, although there were some ambiguities in their advice. Treatment recommendations were based primarily on blood pressure levels which were set at about 160 mm Hg systolic and/or 90 mm Hg diastolic. The threshold levels were based mainly on the cut-off blood pressure levels used in randomised trials of anti-hypertensive drug treatment, rather than the estimated magnitude of treatment benefit. Each of the guidelines acknowledged the important effect of associated cardiovascular disease (CVD) risk factors on the likely benefits of treatment, but did not expand on the magnitude of this effect. No patient-specific estimates of the likely absolute benefits of treatment were provided in any of the guidelines. In contrast the New Zealand guidelines for the management of hypertension recommend the use of explicit estimates of absolute CVD risks and benefits to inform treatment decisions. They were designed to provide
Introduction
In this paper the question: 'which elderly patients should be considered for anti-hypertensive treatment?' is addressed by considering two hypothetical Correspondence: Associate Professor Rod Jackson practitioners with estimates of the likely absolute risk of CVD in patients with different risk factor profiles and with estimates of the absolute benefits of treatment. The New Zealand guidelines recommend that drug treatment be considered in patients with a 5-year risk of CVD of about 10-15% or more; approximately 25 patients with a 10-15% risk would require treatment for 5 years to prevent one CVD event. As elderly patients are generally at higher absolute CVD risk than younger people, the New Zealand recommendation give priority to the treatment of older patients. In order to take account of differences in life expectancy and the medical costs of caring for elderly people, absolute risk-based guidelines can be improved by incorporating potential years of life gained from treatment and the cost-effectiveness of treatment expressed as $/quality adjusted life years gained. Preliminary analyses indicate that the cost-effectiveness of treatment is generally greatest in patients in their 60s and early 70s. Treatment in younger people is not usually very cost-effective because of their low absolute risk of CVD and the cost-effectiveness of treatment in people over about 75 years declines because of the increasing cost of non-CVD morbidity. Conclusions: The explicit assessment of absolute CVD risks and likely treatment benefits in patients with hypertension can usefully inform treatment decisions and provide a more rational basis for initiating therapy than blood pressure levels alone. This approach highlights the generally greater CVD risk and potential treatment benefits in older compared with younger hypertensive patients. The absolute risk-based approach can be further enhanced by providing decision makers with patient-specific data on the potential life years gained from treatment and its cost-effectiveness. When the cost per quality adjusted life year gained is considered in addition to absolute risks and benefits, it can be shown that among people in their mid to late 70s, the additional benefits of treatment related to their higher risk is counterbalanced by their increasing risk of non-CVD morbidity.
patients; the first, a 60-year old women with a blood pressure (BP) of 170/100 mm Hg, and the second, a 70-year-old man with a BP of 150/90 mm Hg. 3 An alternative explicit evidence-based guideline from New Zealand 4,5 is then applied to the two patients. The strengths and weaknesses of the different approaches to treatment decisions and the potential for further developments are discussed.
Treatment recommendations for older patients
The BHS guidelines recommend drug treatment for people aged up to 60 years with BP levels of у160 mm Hg systolic or у100 mm Hg diastolic. It is also recommended that treatment be considered in those patients with diastolic levels between 90-100 mm Hg if the BP is in the upper part of the range, there are other cardiovascular disease (CVD) risk factors or there is target organ damage. Drug treatment is recommended for all patients over 60 years and under 80 years of age with sustained BP levels of у160 mm Hg systolic and/or у90 mm Hg diastolic. Therefore the first patient, the 60-year-old woman with a BP of 170/100 mm Hg, probably meets the treatment criteria although she is on the borderline (ie, 60 years and under, diastolic у100 mm Hg). Similarly the second patient, the 70-year-old man with a BP of 150/90 mm Hg is also on the borderline for treatment (ie, over 60 years, diastolic у90 mm Hg).
There are no specific recommendations for the elderly in the WHO/ISH guidelines, but the treatment thresholds differ slightly from the BHS guidelines. Treatment is recommended in patients with sustained BP levels of 160/95 mm Hg or above. Therefore, patient one meets the treatment criteria because her diastolic level is greater than 95 mm Hg. However, it is unclear whether patient two meets the criteria; his diastolic BP level is on the borderline for treatment consideration among those patients with additional risk factors, but his only additional risk factor is his older age.
The JNC V recommendations for older patients are less clear. Drug treatment is generally recommended for patients with BP levels sustained above 150/90 mm Hg, although in the absence of target organ damage or other risk factors it is considered reasonable to withhold drug treatment in the range 90-94 mm Hg diastolic and 140-149 mm Hg systolic. However the guidelines go on to recommend that among older patients with systolic BP between 140-160 mm Hg, lifestyle modification alone is an acceptable definitive treatment. Thus patient one will meet the treatment criteria but patient two probably does not, unless his older age is considered a major risk factor.
In summary, these three major guidelines, which were all published in the same year, provide inconsistent recommendations for the two hypothetical patients (Figure 1 ). 
The evidence
The evidence on which the above guidelines are based comes mainly from overviews of cohort studies relating BP and other CVD risk factors to stroke and coronary disease mortality and morbidity, 6 and from meta-analyses of randomised trials of BP lowering. 7, 8 The findings of these studies are generally presented in terms of the relative risks (Figure 2 ) of long-term exposure to raised BP, or the relative benefits of treatment ( Figure 3 ). When presented in this form it is not possible to identify the groups of patient most likely to benefit from treatment with any degree of precision, as relative measures have little relevance to decisions about individual patients. In contrast, absolute measures of risks expressed as events per person-time and benefits presented as the numbers of people requiring treatment over a specified time to prevent one event (ie, the number needed to treat or NNT), 9 as shown in Figures 4 10 and 5, 11 give useful information about which patients are most likely to benefit from treatment. As is clearly shown in Figures 4 and 5 , older patients are generally both at higher absolute risk of CVD for a specified BP level and benefit more from treatment than younger patients. Similarly, patients with multiple CVD risk factors are at higher absolute risk and gain more from treatment than patients of the same age with fewer risk factors. 12 When presented with relative measures the question a decision maker needs to ask is: 'relative to what?' For example drug treatment reduces the risk of stroke in a 40-year-old woman with a diastolic BP of 95 mm Hg by about one-third, but it is one-third of an untreated risk of about 3/1000/5 years. 13 In other words the risk is reduced by 1/1000/5 years, so about 1000 similar women would require daily treatment with drugs for 5 years to prevent one stroke (ie, a 5 year NNT of 1000).
An explicit evidence-based approach to treatment decisions
Figures 6, 7 and 8 illustrate an alternative approach to making treatment decisions in patients with raised BP based on the explicit estimation of the 5 year absolute risk of CVD events (including new angina, myocardial infarction, coronary death, transient ischaemic attacks and stroke) in patients with different CVD risk factor profiles. In addition the figures show estimates of the likely benefits of lowering BP, expressed in terms of events prevented per 100 patients treated for 5 years and as 5 year NNTs. These figures can be downloaded in colour or black and white from the Oxford centre for Evidence- Figure 5 Number needed to treat over 5 years to prevent one event (from RCTs).
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Based Medicine web site (http://cebm. jr2.ox.ac. uk/docs/prognosis.html).
The 5 -year risks are based on data from the Framingham Study 13, 14 and the estimated absolute benefits are calculated by applying estimates of the relative benefits of BP lowering (based on meta-analyses of trial data 7, 8, 15 ) to the estimated pre-treatment absolute risks of CVD. It is assumed that reducing BP by 10-15 mm Hg systolic or 5-10 mm Hg diastolic will reduce CVD risk by approximately onethird, whatever the pre-treatment absolute CVD risk. The assumed one-third risk reduction is somewhat greater than the trials predict (ie, between 20-25%), however as the trials were all analysed on an intention-to-treat basis, they are likely to underestimate the true benefit of treatment. The assumption of a similar relative benefit in all patients, whatever the absolute risk, is consistent with the evidence. 15 The New Zealand guidelines for the management of raised BP are based on the evidence of absolute risks and benefits ( Figures 6, 7 and 8 ). These guidelines recommend that 'an estimated 5 year risk of a major CVD event of approximately 10% or more is a reasonable starting point for discussion with a patient regarding pharmacological treatment'. 4 It is acknowledged that there is no obvious cut-off point at which treatment should be instituted and therefore the patient and their doctor should make a decision about treatment once the relevant information on potential risks and benefits have been discussed. The 10% 5 year risk was suggested as a starting point for discussion' following an informal review by the guideline development team of a range of potential patients, but is clearly arbitrary.
Of note the estimated 5 year CVD risk in the hypothetical patients described in the introduction are 5-10% for patient one, the 60-year-old woman with a BP of 170/100 mm Hg, and 15-20% for the 70-yearold man with the BP of 150/90 mm Hg. Moreover the 5 year NNT is 40 for patient one but only 17 for patient two, despite his significantly lower BP. This illustrates the potential weakness of making treatment decisions based primarily on a BP level. If the New Zealand guideline approach is followed, it is likely that the 70-year-old man with a BP level of 150/90 mm Hg would receive priority for drug treatment over the 60-year-old woman with a higher BP, given the greater absolute benefit of treatment in the older patient.
Two potential weaknesses of the New Zealand approach are first, that patient one may develop irreversible vascular damage as a result of her ongoing exposure to high BP and second, that no account is taken of the potential extra years of life a 60-yearold would gain from a prevented CVD event compared with the years gained from preventing an event in a 70-year-old. With respect to the reversibility of risk, observational studies indicate that prolonged exposure to an approximate 9/5 mm Hg difference in systolic/diastolic BP is associated with an observed 35% difference in the incidence of stroke and a 21% difference in coronary heart disease, 15 while trials indicate that dropping BP by approximately 10-12/5-6 mm Hg for about 5 years reduces stroke risk by approximately 38% and CHD risk by about 16%. Therefore it appears that most of the risk is reversible within about 5 years; in fact the average time from initiation of therapy to CVD event in the trials was considerably less than 5 years. With respect to the extra potential years of life gained by preventing events in younger vs older patients, estimates of life years and quality adjusted life years (QALY) gained by treating the same number of patients in different age groups shows the higher absolute benefits in the elderly more than outweigh the additional life expectancy in younger people, particularly when the value of future life years are discounted. 16 A shortcoming of all current hypertension management guidelines is the lack of any explicit information on the cost-effectiveness of therapy. The New Zealand guidelines allow patients to be ranked by the magnitude of the absolute treatment benefit, which is a crude proxy for ranking by cost-effectiveness, however they do not provide enough information to allow comparisons of the absolute costeffectiveness of treating hypertension in particular patients with the cost-effectiveness of other treatments, for example lipid lowering therapy. Without this type of information it will never be possible to rationally choose between competing claims on health care resources. The necessary data is available to make such comparisons and numerous estimates of cost per quality adjusted life year gained have been made for a range of interventions. Unfortunately few analyses use identical methodology and assumptions and in general are not designed to be individualised to specific patients. Simple tools which allow physicians to make comparable patient-specific estimates of cost-effectiveness of say lipid modifying vs BP-lowering treatments are now required to improve the usefulness of explicit evidence-based approaches to the management of hypertension.
An important consideration in cost-effectiveness analyses of anti-hypertensive treatment in the elderly is whether or not future medical costs incurred as a result of preventing CVD deaths should be included. A recent study comparing the cost per QALY with and without the inclusion of future costs had very little effect on the results for younger people but a significant effect on the cost per QALYs for people over 75 years. 16 When future costs were not included anti-hypertensive treatment was most cost-effective in the elderly, but when they were included, treatment was generally lowest in middleaged people. These analyses are preliminary and require further development to identify those patients in whom treatment is most cost-effective.
Conclusion
In summary, the explicit assessment of absolute CVD risks and treatment benefits can usefully inform anti-hypertensive treatment decisions. There is less urgency to initiate drug treatment in patients at low absolute CVD risk, as much of the risk appears to be reversible. Therefore it is reasonable to persevere with non-pharmacological treatment for longer in these patients. The appropriate level of risk at which to initiate treatment is somewhat arbitrary and consideration of patient preferences and ultimately cost-effectiveness and the opportunity costs, will be required if treatment decisions and resource allocation decisions are to be made on a rational basis.
